Epigenomics axes costs
Berlin – Despite intense marketing measures, revenues from Epigenomics’ Epi proColon bowel cancer test remain flat. Along with its QII/2011 numbers, the Berlin-based in vitro diagnostic specialist revealed strict cost-saving measures. About half of the firm’s staff of 84 will be sacked. Epigenomics is currently losing more than a10m annually, but has about EUR20m in the bank.